EHA 2018: Response Rates Improve Significantly With 3-drug Combination for Diffuse Large B-Cell Lymphoma
Adding polatuzumab vedotin to bendamustine and rituximab resulted in a significantly higher rate of complete responses by PET scan
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.